Drug maker Shire said on Tuesday it was seeking to buy Baxalta (BXLT.N), a company spun-off by Baxter International last month, for $30 billion to forge the leading global specialist in rare diseases.
The London-listed group went public with its approach after the U.S. firm turned it down during private talks last month.
Baxalta rebuffed the offer on Tuesday and said in a statement that Shire’s unsolicited offer significantly undervalued the company.
Full content: The New York Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
